To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Bladder Cancer

Brielle Urciuoli
Immunotherapy is being tested in the second-line setting for metastatic bladder cancer. Pending trial results, the role of chemotherapy for this patient population may change.
Kristie L. Kahl
Phase 2 study results showed that patients with metastatic or unresectable, FGFR-positive bladder cancer may have a third-line option for treatment.
Silas Inman
The FDA has incorporated PD-L1 status into the labels for Keytruda (pembrolizumab) and Tecentriq (atezolizumab) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma, based on lower overall survival (OS) rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1–low expressing platinum-eligible urothelial carcinoma.
Oncolytic, or engineered, viruses that infect and kill cancer cells are showing promise.
Katie Kosko
Enfortumab vedotin may be a potential novel therapy for patients with locally advanced or metastatic urothelial cancer, according to updated phase 1 study findings presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Brielle Urciuoli
PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.
Ahrang Jung
Patients with non-muscle invasive bladder cancer experience high levels of distress, according to one study.
Brielle Urciuoli
Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.
Brielle Urciuoli
The combination use of Cyramza (ramucirumab) plus docetaxel showed improvements in objective response rate (ORR) and a positive trend in overall survival (OS) among patients with advanced bladder cancer, according to additional results from the phase 3 RANGE trial.
Brielle Urciuoli
In particular, patients whose tumors have certain genetic mutations may respond especially well to this combination approach.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other